OTCPK:MDIT

Stock Analysis Report

Medite Cancer Diagnostics

Executive Summary

Medite Cancer Diagnostics, Inc. operates as a medical technology company.

Snowflake

Fundamentals

Imperfect balance sheet and overvalued.

Risks

  • Medite Cancer Diagnostics has significant price volatility in the past 3 months.
  • Medite Cancer Diagnostics's last earnings update was 307 days ago.
  • Medite Cancer Diagnostics is not covered by any analysts.

Similar Companies

Share Price & News

How has Medite Cancer Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-9.2%

OTCPK:MDIT

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

-8.0%

OTCPK:MDIT

9.7%

US Medical Equipment

1.9%

US Market

MDIT underperformed the Medical Equipment industry which returned 9.6% over the past year.

MDIT underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

MDITIndustryMarket
7 Day-9.2%1.5%0.8%
30 Day163.4%0.7%3.4%
90 Day210.8%2.4%2.1%
1 Year-8.0%-8.0%10.6%9.7%4.2%1.9%
3 Year-87.5%-87.5%70.2%65.0%46.7%37.2%
5 Year-96.7%-96.7%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Medite Cancer Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medite Cancer Diagnostics undervalued based on future cash flows and its price relative to the stock market?

0.91x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Medite Cancer Diagnostics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Medite Cancer Diagnostics to establish if it is available at substantial discount.


Price Based on Earnings

Medite Cancer Diagnostics is loss making, we can't compare its value to the US Medical Equipment industry average.

Medite Cancer Diagnostics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Medite Cancer Diagnostics, we can't assess if its growth is good value.


Price Based on Value of Assets

Medite Cancer Diagnostics is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Medite Cancer Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medite Cancer Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of MDIT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Medite Cancer Diagnostics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Medite Cancer Diagnostics performed over the past 5 years?

-60.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Medite Cancer Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Medite Cancer Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Medite Cancer Diagnostics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Medite Cancer Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Medite Cancer Diagnostics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Medite Cancer Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Medite Cancer Diagnostics's financial position?


Financial Position Analysis

Medite Cancer Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Medite Cancer Diagnostics's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Medite Cancer Diagnostics's level of debt (94%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (163.1% vs 94% today).

Operating cash flow is negative therefore debt is not well covered.

Unable to confirm if the interest payments on Medite Cancer Diagnostics's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.9x debt.


Next Steps

Dividend

What is Medite Cancer Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Medite Cancer Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Medite Cancer Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Medite Cancer Diagnostics has not reported any payouts.

Unable to verify if Medite Cancer Diagnostics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Medite Cancer Diagnostics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Medite Cancer Diagnostics's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average board tenure


CEO

Medite Cancer Diagnostics has no CEO, or we have no data on them.


Board Age and Tenure

1.8yrs

Average Tenure

55.5yo

Average Age

The average tenure for the Medite Cancer Diagnostics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$20,00023 Oct 18
Northlea Partners Ltd.
EntityCompany
Shares266,667
Max PriceUS$0.075
BuyUS$679,00019 Oct 18
Lewis Asset Management, Corp.
EntityCompany
Shares9,053,333
Max PriceUS$0.075

Ownership Breakdown


Management Team

  • Susan Weisman (58yo)

    Consultant

    • Tenure: 1.7yrs
    • Compensation: US$258.99k
  • Jeff Rencher (52yo)

    Chief Marketing & Business Development Officer

    • Tenure: 2.3yrs
    • Compensation: US$160.10k

Board Members

  • John Abeles (75yo)

    Director

    • Tenure: 20.3yrs
    • Compensation: US$123.88k
  • Joel Kanter (62yo)

    Independent Director

    • Tenure: 1.8yrs
  • Gregory Fortunoff (49yo)

    Director

    • Tenure: 1.7yrs
  • William Lewis (43yo)

    Chairman of Board

    • Tenure: 0yrs
    • Compensation: US$168.66k

Company Information

Medite Cancer Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medite Cancer Diagnostics, Inc.
  • Ticker: MDIT
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$5.946m
  • Shares outstanding: 86.18m
  • Website: https://medite-group.com

Number of Employees


Location

  • Medite Cancer Diagnostics, Inc.
  • 10524 Moss Park Road
  • Suite 204-357
  • Orlando
  • Florida
  • 32832
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDITOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 1998

Biography

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:55
End of Day Share Price2019/09/17 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.